Agreement extends use of proprietary technology for enabling users of analytical instruments to automate the analysis of data-intensive applications
BioAnalyte has broadened its licence agreement with a United Kingdom firm that already produces core components in its Trawler product, to create Enterprise Trawler - aimed at pharmaceutical, industrial and other high throughput applications.
The agreement with Positive Probability (PPL) extends BioAnalyte's use of proprietary technology for enabling users of analytical instruments to automate the analysis of data-intensive applications, such as assessing diagnostic candidates for early cancer detection.
BioAnalyte's products are part of the biotechnology sub-sector known as bioinformatics, or the application of information science to biology for the purposes of uncovering subtle relationships in complex and abundant data.
"This broadened licence allows BioAnalyte to increase sales of our highest margin products said Peter Leopold, president of BioAnalyte.
"With PPL's tools, our picks and shovels are sharper and stronger and now they reach farther than those of our competitors".
BioAnalyte produces a subscription version of the Trawler program called Nets Trawler, which is a low-cost entry point, intended to widen adoption of the BioAnalyte platform.
"Our Nets Trawler product, which also uses PPL's engine, is designed to penetrate disposables markets.
"Nets Trawler generates subscription revenue and attracts users to purchase the upgrade.
"With the new Enterprise Trawler, we will reel in revenues from capital budgets as well", Leopold added.
"Our growing partnership with BioAnalyte allows us instant access to a widespread and dynamic customer base as well as an opportunity to bring our algorithms to the crux of the most urgent problems in genomics and proteomics said Anthony Ferrige, applications director of Positive Probability .
"We intend to leverage BioAnalyte's position within the analytical instruments market to gain maximal adoption of our engine".
